Engflag

Cetil-CV

Quick links to important sections

Cetil-CV

Cetil-CV_DE

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cetil-CV

What is Cetil-CV?

Cetil-CV is a prescription-only, synthetic fixed dosage combination medication, primarily classified as an Antibiotic / beta-Lactamase Inhibitor. It is administered via the oral route, typically available as a tablet, oral suspension, or dry syrup. The core antibiotic component, Cefuroxime, is categorized as a second-generation Cephalosporin antibiotic. This combination formulation is designed for enhanced stability and a wider spectrum of activity compared to single-agent treatments. As a fixed dosage combination, Cetil-CV is explicitly developed to maximize the effectiveness of the antibiotic component against a variety of bacterial infections.

The Fixed Dosage Combination: Cefuroxime and Clavulanic Acid

Cetil-CV contains two distinct active ingredients: Cefuroxime (supplied as the prodrug Cefuroxime axetil) and Clavulanic Acid (supplied as Clavulanate). Cefuroxime is the primary therapeutic agent, providing a bactericidal effect by inhibiting the development of the bacterial cell wall. Clavulanic Acid, a non-antibiotic component, serves a protective function by neutralizing the defense mechanisms used by certain bacterial strains. This dual action means the medicine is formulated to attack bacteria while simultaneously neutralizing their common defense mechanisms. Analogues with the same composition are also available, reflecting the established utility of this specific two-agent formulation.

Why is This Combination Necessary for Bacterial Infections?

This combination is used to ensure the antibiotic remains functional against strains that have developed resistance mechanisms, offering a broad-spectrum antibiotic benefit. Many bacteria produce enzymes called beta-lactamases, which can destroy antibiotics like Cefuroxime before they can act; Clavulanic Acid works as an inhibitor to deactivate these enzymes. By protecting Cefuroxime from degradation, the fixed dosage combination retains its ability to target and destroy the invading bacteria, especially those categorized as drug-resistant bacterial strains. The synergistic action of beta-lactamase inhibitors with beta-lactam antibiotics expands the therapeutic range for Cefuroxime against resistant pathogens. This dual-component approach is utilized to maintain effective treatment and manage bacterial infections, such as certain respiratory or urinary tract infections, where microbial resistance is a factor.

Regulatory References

  1. NIH Reference

What side effects are possible with Cetil-CV?

Possible Side Effects and Safety Information

Adverse reactions associated with Cefuroxime and Clavulanic Acid (Cetil-CV) are officially documented and classified by frequency and System-Organ-Class (SOC) in regulatory labeling. The most frequently observed effects, categorized as Common, include Diarrhoea, Nausea, Headache, Dizziness, and fungal infections such as Candidiasis. Uncommon events include Vomiting, Abdominal pain, Rash, and transient changes in hematologic parameters like Leukopenia and Thrombocytopenia.

The safety profile highlights the potential for Serious Adverse Reactions (SARs), which are rare but clinically significant. These include severe immediate hypersensitivity reactions like Anaphylaxis and severe cutaneous adverse reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The label also documents the risk of Pseudomembranous colitis and significant, though often reversible, Hepatic Dysfunction, including Cholestatic Jaundice, which may have a delayed onset.

Safety Considerations for Specific Populations are documented in the official regulatory texts. For individuals with severe renal impairment, there is an increased risk for adverse neurological events, notably Convulsions, due to reduced drug clearance. A documented constraint is the required caution for patients with a known history of hypersensitivity to beta-lactam antibiotics, which is a high-level safety consideration related to potential cross-sensitivity. This structured regulatory information frames the overall understanding of the medicine’s risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

Taking more than the prescribed dose of Cetil-CV (a combination of cefuroxime and clavulanic acid) can lead to an overdose. The immediate and most common signs of an acute overdose typically involve the digestive system, including nausea, vomiting, and diarrhea.

In rare or more severe cases, especially in individuals with existing kidney impairment, a significant overdose of the cephalosporin component (cefuroxime) can cause signs of central nervous system irritation. These symptoms may include neuromuscular excitability or the development of seizures (convulsions).

If you suspect you or someone else has taken an excessive dose of Cetil-CV, it is essential to seek immediate medical attention. Contact a poison control center or emergency services right away. Management of an overdose is primarily supportive, focusing on managing symptoms and maintaining vital functions. While not always necessary, medical professionals may consider measures like hemodialysis to help remove the drug from the bloodstream in severe cases, particularly if the individual has poor kidney function.

Always adhere strictly to your healthcare provider’s prescribed dosage.

Therapeutic Uses of Cetil-CV

What Cetil-CV Treats: Main Uses and Benefits

The Cefuroxime and Clavulanic Acid combination is considered relevant for managing bacterial infections in clinical settings that involve acute or unstable symptom patterns. The antibiotic component is indicated for numerous infections due to susceptible bacteria.

The therapy may be part of symptomatic management for conditions presenting with acute episodes, including respiratory tract infections, skin and soft tissue infections, uncomplicated urinary tract infections, and Early Lyme Disease (Erythema Migrans). The medication helps address symptom clusters such as high fever, cough, sinus pressure, and localized redness or swelling that typically accompany these acute bacterial states. The resulting therapeutic benefit contributes to easing the overall symptom load and helps improve day-to-day comfort.

The combination is applied in contexts marked by increased discomfort or tension when bacteria may be resistance-prone. This supports patients during difficult episodes by easing distress and assists with maintaining functional stability.

“The combination is relevant in scenarios where supportive symptom management is appropriate, particularly during phases when symptoms become more noticeable.”

Quick Fact: Supports Management of Symptoms Related to Respiratory and Local Inflammation

Regulatory References

  1. DailyMed official labeling overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Cetil-CV?

Eligibility for Cefuroxime and Clavulanic Acid (Cetil-CV) is defined by official regulatory documentation, focusing on absolute contraindications, age, and pre-existing conditions.

Absolute Non-Eligibility (Contraindications)

You must not use this medicine if you have a known hypersensitivity or allergy to Cefuroxime, Clavulanic Acid, any excipients, or any other Cephalosporin antibiotic. A history of severe allergic reaction (e.g., anaphylaxis) to any beta-lactam antibacterial agent (like penicillins) is also a formal contraindication due to the risk of cross-sensitivity. Regulatory labels also prohibit use in patients with a history of Cefuroxime-associated Hemolytic Anemia or certain other severe skin reactions.

Age- and Condition-Based Restrictions

Population Group Regulatory Status
Infants under 3 months Safety and efficacy have not been established for oral formulations.
Severe Renal Impairment Use is conditional; requires a restricted, adjusted dosing regimen.
Phenylketonuria (PKU) The oral suspension formulation is restricted due to the presence of phenylalanine.
Pregnant Women Use is conditional; reserved for when the benefit clearly outweighs the potential risk.

Use in adults and adolescents (13 years and older) is generally approved, and pediatric use is established for children 3 months to 12 years of age.

What should I know about interactions with other medicines?

Cetil-CV contains cefuroxime axetil and clavulanic acid. When taking this medicine, interactions with certain other products can occur, affecting either the antibiotic’s effectiveness or the safety of the combination. Therefore, it is important to disclose all current medications, supplements, and herbal products to a healthcare provider.

Documented Interactions

  • Antacids and Acid-Reducing Agents: Medicinal products that decrease gastric acidity, such as antacids (containing aluminum or magnesium) and ranitidine, can reduce the bioavailability (absorption) of the cefuroxime component. This may lower the concentration of the antibiotic in the body. If an antacid must be taken, regulatory documents suggest spacing the administration by taking the antacid at least two hours before or two hours after Cetil-CV.
  • Probenecid: Co-administration of the gout medicine probenecid can significantly increase and prolong the blood level of cefuroxime by inhibiting its elimination from the kidneys. This may increase the risk of side effects, and this combination is generally not recommended.
  • Oral Contraceptives: Like other broad-spectrum antibiotics, Cetil-CV may theoretically reduce the effectiveness of combined oral estrogen/progesterone contraceptives by interfering with the normal gut flora needed for hormone reabsorption. An additional, non-hormonal method of birth control should be used during treatment and for a short period afterward.
  • Potent Diuretics: The antibiotic should be used with caution in patients concurrently receiving potent diuretics, as these agents may carry a risk of affecting kidney function. Regular monitoring may be advised.

Mechanism of Action

How Cetil-CV Works

Cetil-CV operates via a dual-mechanistic cascade targeting bacterial structural integrity and resistance pathways. The main antibiotic component, Cefuroxime, exerts its effect by acting within the domain of bacterial cell wall synthesis. It achieves this by binding to and inactivating penicillin-binding proteins (PBPs), which are critical enzymes required for the final cross-linking steps of the bacterial cell wall structure. This targeted interference prevents the bacteria from maintaining their rigid structure, ultimately causing them to lyse (rupture), resulting in cell lysis and loss of bacterial viability.

Simultaneously, the second component, Clavulanic Acid, engages a crucial resistance modulation mechanism. It functions as a suicide inhibitor that specifically and irreversibly targets and binds to beta-lactamase enzymes produced by resistant bacteria. By inactivating these destructive enzymes, Clavulanic Acid shields Cefuroxime from degradation, which allows the Cefuroxime component to successfully engage its primary mechanistic target. The sequential activity of both components leads to an enhanced mechanistic effect on bacterial viability through the targeted inhibition of cell wall synthesis.

Dosage and Administration Information

How to Use Cetil-CV — Official Administration Guidelines

Cetil-CV (Cefuroxime and Clavulanic Acid) is an oral medicine that must be taken strictly according to the instructions provided by your prescriber.

Procedural Instructions

Administration Scope Official Labeled Instruction
Route of Administration Oral (by mouth).
Method of Administration The tablet must be swallowed whole with water. Do not crush, chew, or break the tablet, as this may alter the intended release of the medicine.
Timing in Relation to Meals May be administered without regard to food (with or without a meal). Taking it at a fixed time each day is recommended for consistency and effectiveness.
Frequency Typically prescribed every 12 hours (twice daily) for a specified duration, often 5 to 10 days.
Dosage The dose varies by patient age and condition; common adult doses are 250 mg or 500 mg every 12 hours. Dosage adjustment is explicitly required for patients with impaired renal function.
Missed Dose Rule If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and continue the regular dosing schedule. Do not double the dose.

Use Protocol

The full course of treatment must be completed, even if the user begins to feel better, to adhere to the standardized use protocol. These instructions ensure the correct administration method and schedule are followed for the drug's intended action.

Recent Clinical Evidence

Evidence Supporting Use in Respiratory Tract Infections

Research for this combination in respiratory conditions, such as pneumonia and bronchitis, includes Randomized Controlled Trials (RCTs) examining measurements of symptom change and pathogen clearance in adults and adolescents. Findings describe patterns related to symptom evolution during the defined study periods. The number of large-scale RCTs focusing solely on the fixed-dose combination (FDC) remains limited compared to trials on the core antibiotic component alone.

Evidence Supporting Use in Urinary Tract and Skin Infections

Evidence for uncomplicated Urinary Tract Infections (UTIs) and Skin and Soft Tissue Infections (SSTIs) is largely supported by observational studies and extensive in vitro susceptibility testing. Studies monitored changes in symptoms and examined the ability of the combination to achieve bacteriological clearance of pathogens, particularly those with beta-lactamase-producing traits. As with respiratory uses, the evidence quality varies, and dedicated FDC-specific trials remain sparse across these indications.

Evidence Supporting Use in Early Lyme Disease

Research exploring the combination’s use in Early Lyme Disease (Erythema Migrans) is rooted in established regulatory trial data for the Cefuroxime component and the context of authoritative clinical guidelines. Studies monitored the change in size or severity of the skin lesion. The research on the clavulanic acid component focuses primarily on its evaluation in managing potential co-infections, and is not focused on direct efficacy against the Lyme pathogen itself.

Long-Term Research and Areas of Uncertainty

Most clinical trials assess short-term or episodic symptom patterns, with typical follow-up durations ending shortly after treatment completion. Long-term outcomes or the durability of effects beyond a few weeks are not fully established. Data for certain groups, such as very young children or individuals with multiple complex health conditions, remain insufficient. A primary research limitation is the continued lack of extensive, dedicated FDC-specific RCTs across all studied indications.

Key Studies & References

  1. Cefuroxime - StatPearls - NCBI Bookshelf (Review of Cefuroxime Indications and Activity)
  2. Label: CEFUROXIME AXETIL tablet - DailyMed (FDA-referenced Drug Label)
  3. What are the most up to date guideline recommendations for the treatment of Lyme disease? (Clinical Guidance Summary)

Frequently Asked Questions (FAQ)

Common questions about Cetil-CV (FAQ)

Q: Can I consume alcohol while on this medication?

Official product information for this medicine generally does not list a specific contraindication or warning against consuming alcohol, unlike some other antibiotics. However, official information does note that common side effects can include dizziness and headache. Due to the potential for these side effects, caution is generally recommended. Patients should consult their healthcare professional for specific guidance.

Q: What happens if I accidentally take two doses at the same time?

Taking more than the prescribed amount is considered an overdose. According to regulatory documentation, overdosage of this type of antibiotic, especially in individuals with reduced kidney function, may potentially cause irritation of the central nervous system that could lead to seizures or convulsions. In cases of overdose, management is typically supportive.

Q: What are the most common side effects of Cetil-CV?

Official product information, based on clinical trial data, reports that the most frequent adverse reactions often involve gastrointestinal issues. These include diarrhea, nausea, and vomiting. Other very common effects often reported include headache. Diarrhea is typically cited as the most common side effect overall.

Q: How long do I need to take the medicine for?

The length of your treatment is determined by your healthcare provider. Official labeling indicates the full course of therapy is generally 5 to 10 days and should be completed as prescribed to target the infection successfully. Treatment durations are specified by the prescriber.

Q: How should I safely get rid of the remaining tablets?

Official guidance from regulatory bodies generally recommends against flushing unused or expired medicine down the toilet or placing it in household trash. To ensure safety and protect the environment, options such as local drug take-back programs or following specific disposal instructions provided by a pharmacist are recommended.

Q: Does Cetil-CV interact with antacids?

Yes, regulatory documents indicate that Cetil-CV can interact with certain types of antacids and acid-reducing drugs. These products can reduce the absorption of the antibiotic component (cefuroxime). Official prescribing information indicates that a separation of doses by at least two hours is often recommended when taking an antacid.

How should Cetil-CV be stored and disposed of?

How to Store and Dispose of Cetil-CV?

The official storage and disposal requirements for Cetil-CV (Cefuroxime and Clavulanic Acid tablets) are defined by strict regulatory standards to maintain the product's 24-month stability.

Mandatory Storage Conditions

Requirement Condition
Temperature Store below 25°C
Protection Must be protected from light and moisture

Packaging and Disposal Rules

To ensure efficacy, the medicine must be kept in the original container, tightly closed, and stored out of reach of children. The integrity of the packaging is essential to protect the tablets from moisture. Any unused or expired Cetil-CV must be disposed of properly according to local regulations for pharmaceutical waste, ensuring it is not consumed by others.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cetil-CV found in:

A-Z Index: